Heramvand, Nadia
Masyuk, Maryna http://orcid.org/0000-0003-2856-6893
Muessig, Johanna M.
Nia, Amir M.
Karathanos, Athanasios
Polzin, Amin
Valgimigli, Marco
Gurbel, Paul A.
Tantry, Udaya S.
Kelm, Malte
Jung, Christian
Funding for this research was provided by:
Medicure
Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 1116)
Heinrich-Heine-Universität Düsseldorf
Article History
Accepted: 5 April 2022
First Online: 28 April 2022
Declarations
:
: Paul A. Gurbel reports grants and personal fees from Bayer HealthCare LLC, Otitopic Inc, Amgen, Janssen, Medicure, and US WorldMeds LLC; grants from Instrumentation Laboratory, Haemonetics, Medicure Inc, Idorsia Pharmaceuticals, and Hikari Dx; personal fees from UpToDate. Paul A. Gurbel is a relator and expert witness in litigation involving clopidogrel. In addition, Paul A. Gurbel holds two patents, Detection of restenosis risk in patients and Assessment of cardiac health and thrombotic risk in a patient. Nadia Heramvand reports a grant from Medicure Inc. Marco Valgimigli reports research grants to the Inselspital from Medicure Inc. for the conduct of the FABOLUS FASTER Trial.